Trial · NCT03311009
A Study With GLPG1972 in Osteoarthritis Subjects
NCT03311009, Phase 1, Completed, Lakefront Biotherapeutics NV
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study With GLPG1972 in Osteoarthritis Subjects. Trials, record NCT03311009. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03311009
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study With GLPG1972 in Osteoarthritis Subjects
- NCT number
- NCT03311009
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 30 participants, actual
- Lead sponsor
- Lakefront Biotherapeutics NV
- Conditions
- Osteoarthritis
- Interventions
- GLPG1972 cohort 1, GLPG1972 cohort 2, GLPG1972 cohort 3, Placebo
- First posted
- 2017-10-16
- Last updated
- 2017-11-24
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events | From screening until the final follow up visit (day 50) | To assess safety and tolerability of GLPG1972 in OA patients |
| Primary | Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs | From screening until the final follow up visit (day 50) | To assess safety and tolerability of GLPG1972 in OA patients |
| Primary | Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations | Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50) | To assess safety and tolerability of GLPG1972 in OA patients |
| Primary | Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination | Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50 | To assess safety and tolerability of GLPG1972 in OA patients |
| Primary | Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG | Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50) | To assess safety and tolerability of GLPG1972 in OA patients |
| Primary | Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment | Day -1 to days 1 and Day 10 to day 11 | To assess safety and tolerability of GLPG1972 in OA patients |
| Primary | The maximum observed plasma concentration of GLPG1972 (Cmax) | Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43 | To assess PK of GLPG1972 in OA patients |
| Primary | The time (tmax) to reach Cmax of GLPG1972 | Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43 | To assess PK of GLPG1972 in OA patients |
| Primary | The plasma concentration of GLPG1972 24 after the last dose | Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43 | To assess PK of GLPG1972 in OA patients |
| Primary | The area under the plasma concentration time curve from time 0 until the last quantifieble dose | Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43 | To assess PK of GLPG1972 in OA patients |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40826764 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03311009
GET https://conductscience.org/api/trials/v1/NCT03311009/registered